Business
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
Dr. Babar Rao highlights clinically meaningful outcomes with majority of lesions potentially avoiding immediate surgery in non-melanoma Skin Cancer
About this update from Medicus Pharma Ltd.
[{"type":"text","content":"Dr. Babar Rao highlights clinically meaningful outcomes with majority of lesions potentially avoiding immediate surgery in non-melanoma Skin Cancer\nPHILADELPHIA, March 30, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (\"Medicus\" or the \"Company\"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today reported independent clinical validation of its Phase 2 SkinJect® dataset from Dr. Babar Rao, principal investigator of the SKNJCT-003 study and a globally recognized dermatology key opinion leader. Dr. Rao’s independent assessment reinforces the Company’s view that the dataset is clinically meaningful, decision-grade, and supportive of continued development and regulatory engagement. Dr. Rao, speaking in his capacity as principal investigator during the Company’s business update call, stated: “In my view as principal investigator, the dataset is clinically meaningful, supports continued development, and justifies regulatory engagement and further trials.” Independent KOL Validation of Phase 2 Results The SKNJCT-003 study is a randomized, double-blind, three-arm Phase 2 trial evaluating microneedle-mediated delivery of doxorubicin compared with a biologically active device-only control in patients with nodular basal cell carcinoma (BCC). Dr. Rao described that the study design provides a rigorous clinical framework, enabling: Isolation of the incremental therapeutic contribution of doxorubicinEvaluation of both clinical (visual) and histological clearance endpointsInterpretation of outcomes in the context of a biologically active microneedle platform “The clear separation between active drug and device-only control demonstrates a clinically meaningful therapeutic effect on top of a biologically active platform,” Dr. Rao noted. The 200µg cohort at Day 57 demonstrated the highest observed activity in the study, including: ~80% overall response rate73% clinical clearance40% histological clearanceEvidence of continued biological activity over time These findings support the Company’s selection of the 200µg dose as the lead regimen for further development. Dr. Rao highlighted the real-world clinical implications of the dataset, particularly the importance of clinical (visual) clearance: “Approximately three out of four treat...